NorthWest Biotherapeutics Inc (NWBO)

[KRISGO]

Based on the trading pattern over the past couple of months, there appears to be no real fear of missing out among investors. Many have already accumulated shares, and the price only dips slightly unless management issues shares to raise capital, otherwise, it tends to remain stagnant around $0.25.

Approval news combined with this low price could attract new investors or prompt existing holders to add more, potentially creating a squeeze that pushes the stock higher. However, volume will be critical—we would need to see consistent 40–50 million share days for the price to move meaningfully upward.